Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

• Chrisann Kyi,
• Alexia Iasonos,
• Carol Aghajanian,
• Paul Sabbatini,
• Ekaterina Doubrovina,
• Sara Kravetz,
• David Spriggs,
• Richard J O'Reilly,
• Roisin E O’Cearbhaill

Affiliations

Chrisann Kyi

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Alexia Iasonos

Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Carol Aghajanian

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Paul Sabbatini

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Ekaterina Doubrovina

Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Sara Kravetz

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

David Spriggs

Harvard Medical School, Boston, Massachusetts, USA

Richard J O'Reilly

Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Roisin E O’Cearbhaill

Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA